Combination of Magnetic Resonance Spectroscopy and $^{11}$C-Methionine Positron Emission Tomography for the Accurate Diagnosis of Non-Enhancing Supratentorial Glioma

Nijiati Kudulaiti, MD\(^1\)*, Tianming Qiu, MD, PhD\(^1\)*, Junfeng Lu, MD, PhD\(^1\), Huiwei Zhang, MD, PhD\(^2\), Zhengwei Zhang, MD\(^2\), Yihui Guan, MD, PhD\(^2\), Dongxiao Zhuang, MD, PhD\(^1\), Jinsong Wu, MD, PhD\(^1\)

\(^1\)Department of Neurologic Surgery and \(^2\)PET Center, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

Objective: To evaluate whether the combination of magnetic resonance spectroscopy (MRS) and $^{11}$C-methionine positron emission tomography ($^{11}$C-MET PET) could increase accurate diagnostic sensitivity for non-enhancing supratentorial gliomas. 

Materials and Methods: Between February 2012 and December 2017, 109 patients with non-enhanced supratentorial lesions on contrast-enhanced MRI were enrolled. Each patient underwent MRS and $^{11}$C-MET PET before treatment. A lesion was considered to be a glioma when either the MRS or $^{11}$C-MET PET results reached the diagnostic threshold. The radiological diagnosis was compared with the pathological diagnosis or medical diagnostic criteria.

Results: The sensitivity and specificity were 60.0% and 50.0% for MRS and 75.8% and 50.0% for $^{11}$C-MET PET, respectively. Upon combining the two modalities, the sensitivity and specificity of the imaging-based diagnosis prior to surgery reached 89.5% and 42.9%, respectively. Statistically significant differences in the sensitivities were observed between the combined and individual approaches (MRS alone, 89.5% vs. 60.0%, \(p<0.001\); $^{11}$C-MET PET alone, 89.5% vs. 75.8%, \(p=0.001\)). However, no significant differences in specificity were observed between the combined and individual modalities.

Conclusion: The combination of MRS and $^{11}$C-MET PET findings significantly increases accurate diagnostic sensitivity for non-enhancing supratentorial gliomas without significantly lowering the specificity. This finding suggests the potential of the combined MRS and $^{11}$C-MET PET approach in clinical applications.

Keywords: Glioma; Magnetic resonance spectroscopy; Methionine; PET

INTRODUCTION

Gliomas account for 29% and 81% of all primary and malignant cerebral tumors, respectively (1). Currently, structural magnetic resonance imaging (MRI) is the most commonly accepted diagnostic method for identifying gliomas. However, enhancement of low-grade gliomas (LGGS) and certain high-grade gliomas (HGGs) is sometimes not observed on post-contrast T1-weighted imaging (T1WI). This lack of enhancement occurs despite the use of contrast and additional MRI sequences, such as diffusion-weighted imaging, T2-weighted fluid-attenuated inversion recovery (FLAIR), and perfusion-weighted imaging, which may lead to potential difficulties in differentiating non-enhancing...
gliomas from non-tumor lesions arising from gliosis, encephalomalacia, demyelination, or inflammation (2).

To overcome these structural MRI deficiencies, metabolic imaging techniques have been used as supplementary approaches to obtain information on tissue biological processes and diagnose gliomas. Positron emission tomography (PET) and magnetic resonance spectroscopy (MRS) are metabolic imaging techniques with potential applications in cerebral tumor imaging (3). These techniques can be used to acquire information about tumor-related physiological processes, metabolic pathways, and molecular events.

MRS provides important metabolic information on N-acetylaspartate (NAA), choline (Cho), and creatine levels, which are useful for characterizing gliomas and surrounding normal brain tissue (4-6). A previous study reported that, at a maximum Cho/NAA index (CNImax) threshold of 2.0, tumor infiltration in HGGs and LGGs could be predicted with probabilities of 90% and 87%, respectively (7). However, when gliomas invade ventricular systems, blood vessels, scalp fat, and skull lipids can affect MRS image quality, which makes the CNImax unreliable for preoperative diagnosis.

In addition to MRS, various biological processes in gliomas can be noninvasively imaged using PET. Of the numerous radiotracers synthetized to distinguish between brain tumors, $^{11}$C-methionine ($^{11}$C-MET) is highly useful (3, 8, 9). $^{11}$C-MET PET has relatively low background activity in normal brain tissue, which allows it to differentiate between gliomas and non-tumor lesions with high specificity and sensitivity (10). Although the sensitivity of $^{11}$C-MET PET ranges between 76–100% according to different studies, its sensitivity is comparatively lower when there is a higher percentage of non-enhancing LGGs (10).

$^{11}$C-MET PET can still be reliable in areas of reduced MRS image quality, whereas MRS results can be referred to when gliomas are hypometabolic on $^{11}$C-MET PET. Considering the advantages and limitations of $^{11}$C-MET PET and MRS, we sought to assess whether a combination of these imaging techniques could facilitate accurate diagnosis of non-enhancing supratentorial gliomas.

MATERIALS AND METHODS

Study Population

This retrospective study included patients with non-enhancing supratentorial lesions on contrast-enhanced MRI admitted between February 2012 and December 2017. Patients who had previously undergone surgery, chemotherapy, or radiotherapy were excluded. One hundred and nine patients with non-enhanced supratentorial lesions visible on contrast-enhanced MRI were enrolled in this study. MRS and $^{11}$C-MET PET were performed for each patient. Treatment was started within a month of the latest imaging-based diagnosis. Histological diagnosis was based on biopsy or resection, depending on availability. For neurological diseases, diagnoses were made according to medical criteria by two blinded neurologists. The study was approved by the Institutional Review Board of Huashan Hospital, and informed consent was obtained from all study participants.

MRS Imaging

The MRS parameter settings used in this study have been previously published (7). A multivoxel point-resolved spectroscopic sequence (TR/TE, 1700/135 ms; 15-mm section thickness; FOV, 120 x 120 mm; phase encoding, 16 x 16) was used. To achieve water suppression, three chemical shift-selective pulses were used. On T2WI, the size of the chemical shift imaging slice was larger than the largest diameter of the lesion. The region of interest (ROI) was placed on the abnormal signal region on T2WI. Areas of skull lipid and scalp fat were carefully avoided because...
they could have compromised imaging quality. After image acquisition, the raw data were exported to a post-processing workstation.

**MRS Data Processing**

A Siemens Syngo workstation (syngo MultiModality Workplace, Siemens Healthineers) was used for reconstructing and analyzing the raw spectral data. The spatial distribution of the metabolite was generated by fitting a curve to the peak area. Within each volume of interest, Cho and NAA were estimated and expressed as integral ratios. The Cho/NAA index (CNI) was calculated for each voxel. A rainbow-colored look-up table comprising the CNIs was created utilizing an overlaid grid, which suggested the anatomical position of the CNIs. The MRS results were considered positive when CNImax was ≥ 2.0 and negative when CNImax was < 2.0.

**11C-MET PET Imaging**

Each patient underwent 11C-MET PET using a 3D PET scanner (Biograph 64, Siemens Healthineers). Data acquisition began 15 minutes after an intravenous bolus injection of 10 mCi 11C-MET at the PET Center of Huashan Hospital. Fasting was not required for 11C-MET PET because no collateral effects have been reported. Before 11C-MET PET scanning, computed tomography (CT) was performed for attenuation correction and image fusion. A 3D acquisition mode was used to acquire 11C-MET PET images during a 15-minute static scan. The spatial resolution of the CT scanner in the axial and tangential directions was 1.5 mm. By applying manufacturer workstation and post-reconstruction 3D gaussian filter smoothing, image reconstructions were achieved with filtered back projection at a maximum full width of 3.5 mm.

**11C-MET PET Data Processing**

The tumor to normal tissue (T/N) ratio was chosen for semi-quantitative analysis. First, 3D spherical ROIs covering the entire lesion were drawn, and the maximum standardized uptake (SUVmax) value inside the ROI was measured. For the T/N ratio, a circular ROI (7-mm diameter) was placed on the most intense lesion area and centered on the pixel with the SUVmax. Another ROI was positioned on an unaffected corresponding contralateral region. If the lesion had affected the contralateral region, the ROI was placed on an intact region of the contralateral hemisphere (11). The mean radiotracer uptake in the lesion ROI divided by the reference ROI value was defined as the T/N ratio. The 11C-MET PET results were considered positive when the T/N ratio was ≥ 1.3 and negative when the T/N ratio was < 1.3.

**Final Diagnosis**

For histopathological evaluation, samples were obtained by biopsy or resection based on the treatment strategy. When the lesion was resectable, maximally safe lesion resection was conducted with navigation guidance. Otherwise, needle biopsy was performed according to the 11C-MET PET and MRS results. The samples were fixed in 10% formalin and embedded in paraffin. Hematoxylin-eosin stained sections of all of the samples were reviewed by two blinded neuropathologists and categorized according to the 2016 World Health Organization Classification of Tumors of the Central Nervous System. When surgical findings were unavailable, two blinded neurologists made a definite diagnosis according to clinical evidence-based medical diagnostic criteria.

**Statistical Analysis**

For MRS images, a CNImax threshold of 2.0 was set as the cut-off value for distinguishing between gliomas and non-tumor tissues as previously reported (7). Meanwhile, a T/N ratio of 1.3 was applied as the cut-off threshold for 11C-MET PET images (11). These thresholds were used to calculate the sensitivity and specificity. A lesion was considered a glioma when 11C-MET PET or MRS results were positive, and a lesion was classified as non-tumor tissue when 11C-MET PET or MRS results were negative. Following this, the imaging-based diagnostic results were compared with the final diagnosis to determine their diagnostic capability. McNemar’s test was performed to compare the sensitivity and specificity of the combination of 11C-MET PET and MRS as well as those of the individual techniques. A p value of < 0.05 was considered statistically significant. SPSS software (version 21, IBM Corp., Armonk, NY, USA) was used to analyze the data.

**RESULTS**

**Patients**

Patient characteristics and clinical data are summarized in Table 1. Of 109 patients, 72 and 31 had resection- and needle biopsy-based histological diagnoses, respectively. The remaining six patients were diagnosed by two blinded neurologists according to clinical evidence-based medical
diagnostic criteria. These patients were diagnosed with inflammation \((n = 2)\), autoimmune encephalopathy \((n = 1)\), cerebral vasculitis \((n = 1)\), demyelination \((n = 1)\), and epilepsy \((n = 1)\). In the patient with epilepsy, there was abnormal signal in the limbic system on MRI; however, there was no progression during the 3-year follow-up period, leading to the diagnosis of a benign lesion. Patient pathological findings are summarized in Table 2.

### Table 1. Patients’ Characteristics and Clinical Data

| Characteristics          | Value* |
|--------------------------|--------|
| Age (years)              | Range 9–72 |
|                           | Mean 41.3 ± 13.8 |
| Sex (%)                  | Male 47 (56.9) |
|                           | Female 62 (43.1) |
| Location (%)             | Frontal 59 (54.1) |
|                           | Temporal 29 (26.7) |
|                           | Parietal 12 (11.0) |
|                           | Occipital 3 (2.7) |
|                           | Deep cerebral hemisphere 6 (5.5) |
| Diagnostic methods (%)   | Resection 72 (66.1) |
|                          | Biopsy 31 (28.4) |
|                          | Clinical criteria 6 (5.5) |

*Values are shown as numbers of patients unless otherwise indicated.

### Table 2. Pathological Findings of Patients

| Diagnosis                                      | Value (%) |
|------------------------------------------------|-----------|
| Astrocytoma                                    | 42 (38.5) |
| Oligodendroglioma                              | 18 (16.5) |
| Anaplastic astrocytoma                         | 18 (16.5) |
| Anaplastic oligodendroglioma                   | 4 (3.7)   |
| Oligoastrocytoma, NOS                          | 4 (3.7)   |
| Glioblastoma                                   | 3 (2.8)   |
| Dysembryoplastic neuroepithelial tumor          | 2 (1.8)   |
| CNS embryonal tumor                            | 1 (0.9)   |
| CD34-positive neuroepithelial tumor            | 1 (0.9)   |

CNS = central nervous system, NOS = not otherwise specified

### Table 3. Diagnostic Capabilities

|                         | Sensitivity | Specificity | Accuracy     |
|-------------------------|-------------|-------------|--------------|
| MRS                     | 60.0% (57/95) (50.1–69.9%) | 50.0% (7/14) (23.8–73.8%) | 58.7% (64/109) (52.5–67.9%) |
| 11C-MET PET             | 75.8% (72/95) (67.2–84.4%) | 50.0% (7/14) (23.8–73.8%) | 72.5% (79/109) (64.1–80.9%) |
| Combination of MRS and 11C-MET PET | 89.5% (85/95) (83.3–95.7%) | 42.9% (6/14) (17.0–68.8%) | 83.5% (91/109) (79.9–87.1%) |

Values are shown as mean with 95% confidence interval. MRS = magnetic resonance spectroscopy, 11C-MET PET = 11C-methionine positron emission tomography.
Combination of MRS and $^{11}$C-Methionine PET in Diagnosis of Glioma

follows: Twenty astrocytomas, seven oligodendroglialomas, six anaplastic astrocytomas, two dysembryoplastic neuroepithelial tumors, one oligoastrocytoma, one CD34-positive neuroepithelial tumor, and one anaplastic oligodendroglioma. The false negative cases for $^{11}$C-MET PET alone were as follows: Twelve astrocytomas, three oligodendroglialomas, three anaplastic astrocytomas, two dysembryoplastic neuroepithelial tumors, one oligoastrocytoma, and one anaplastic oligodendroglioma. The false positive cases for the combination of MRS and $^{11}$C-MET PET were as follows: Three gliosis, one focal cortical dysplasia, one granuloma, one demyelination, one inflammation, and one autoimmune encephalopathy. The false negative cases for the individual and combined approaches were as follows: Five astrocytomas, two oligodendroglialomas, two dysembryoplastic neuroepithelial tumors, and one oligoastrocytoma.

**Effect on Clinical Management**

A cross table of the $^{11}$C-MET PET and MRS results are presented in Table 4. Of the recruited patients, 45 had a normal CNImax; however, 29 (64.4%; 29/45) patients were reconsidered for surgery because positive $^{11}$C-MET PET uptake (i.e., T/N ratio $\geq$ 1.3) was detected. The treatment of these patients could have been delayed if the results had been based on MRS alone (Fig. 2).

Conversely, of the 30 patients who were misdiagnosed earlier due to reliance on $^{11}$C-MET PET scans alone, 14 (46.7%; 14/30) benefited from the supplementary evidence provided by MRS (Fig. 3).

**DISCUSSION**

$^{11}$C-MET is a sensitive radiotracer for glioma detection because it can distinguish between gliomas and non-neoplastic pathologies with high sensitivity and specificity. Such differentiation is possible because of the relatively low background activity of $^{11}$C-MET in normal brain tissue. As a result, $^{11}$C-MET has been applied to the diagnosis and prognosis of gliomas (12, 13), differentiation of glioma recurrence from radiation injury (14, 15), and surgical (11, 16) and radiotherapy planning (17, 18).

Previous research has established that $^{11}$C-MET PET is more accurate for glioma diagnosis than CT (19), and other studies have suggested that $^{11}$C-MET PET is superior to MRI and $^{18}$F-fluorodeoxyglucose PET (12, 20). Ribom et al. (13) reported increased $^{11}$C-MET uptake in 30/32 (94%) LGGs, whereas only 12/32 (38%) showed increased $^{11}$C-MET uptake with contrast enhancement. In our study, increased $^{11}$C-MET uptake was detected in 94/109 (86.2%) gliomas. $^{11}$C-MET PET accuracy for the differential diagnosis of gliomas has been shown in several studies. In LGGs and HGGs, the overall sensitivity of $^{11}$C-MET PET ranged from 76% to 100% (10). In most studies, the T/N ratio was routinely used for calculating the sensitivity and specificity. The cut-off value was typically set as 1.3, and the sensitivity and specificity of $^{11}$C-MET PET for glioma diagnosis were 87% and 89%, respectively (11). Applying the same T/N ratio cut-off value in this study, the $^{11}$C-MET PET sensitivity reached 75.8%. This finding might be explained by the sensitivity being reduced with the inclusion of a higher proportion of gliomas (10). Moreover, clinicians are more concerned with overall $^{11}$C-MET PET accuracy in practice. Our results had an accuracy of 72.5%, whereas Herholz et al. (8) reported an overall $^{11}$C-MET PET accuracy of 79% for a large-scale study.
of 196 patients.

Although $^{11}$C-MET PET can provide additional diagnostic information, in clinical practice, it is not the first choice for glioma differentiation due to its use of radioisotopes, cost, and long acquisition times. Conversely, MRS can be obtained during routine MRI and is, thus, cheaper and more convenient. This technique has been widely used to acquire additional diagnostic information and reflects the histological features of gliomas. In LGGs with hypometabolic $^{11}$C-MET uptake, MRS is better than $^{11}$C-MET PET at detecting the metabolic features of gliomas. Therefore, MRS is a valuable tool for tumor differentiation, grading, and biopsy and radiotherapy planning (4, 21-23). Previous research on the relationship between glioma metabolism and the CNI has revealed that CNI thresholds of 2.0, 1.5, 1.0, and 0.5 appeared to predict tumor-containing samples with probabilities of 90%, 79%, 60%, and 38% for HGGs and 87%, 67%, 39%, and 16% for LGGs, respectively (7).

In our study, the CNI$_{max}$ was > 2.0 in 79/109 patients; however, MRS indicated a diagnostic sensitivity of only 60.0%. This finding could be attributed to the limitations of MRS. First, the results depended on sequence settings. Thus, parameter optimization is crucial for securing reliable results. Second, MRS requires full patient cooperation because patient movement affects the signal-to-noise ratio and leads to an unstable baseline. Moreover, tumor heterogeneity may result in a false-negative result. Finally, the image quality will be affected when gliomas occupy or are near ventricular systems, skull lipids, or scalp fat. Thus, for lesions located in these areas, $^{11}$C-MET PET could yield a better diagnosis than that of MRS.

Considering the imaging characteristics of $^{11}$C-MET

---

Fig. 2. Representative case of anaplastic oligodendroglioma in 53-year-old man. 
A. T1-weighted MRI showing low-intensity lesion in right temporal lobe. B. T2-weighted MRI showing hyperintense lesion in right temporal lobe. C. FLAIR MRI outlining margin of lesion. D. Non-enhanced lesion on post-contrast T1-weighted MRI acquired after Gd-DTPA injection. E. MRS result showing CNI$_{max}$ of 1.65. F. $^{11}$C-MET PET showing strong MET uptake in lesion (SUV$_{max}$, 5.4; T/N ratio, 3.3). Surgery was performed based on combined MRS and $^{11}$C-MET PET findings, and diagnosis was confirmed as anaplastic oligodendroglioma (WHO III). White square (□) shows ROI for CNI$_{max}$, and white circle (○) shows ROI for calculating T/N ratio. Cho = choline, CNI$_{max}$ = maximum Cho/NAA index, FLAIR = fluid-attenuated inversion recovery, Gd-DTPA = gadolinium-diethylenetriamine pentaacetic acid, MET = methionine, NAA = N-acetylaspartate, ROI = region of interest, SUV$_{max}$ = maximum standardized uptake, T/N = tumor to normal tissue, WHO = World Health Organization.
PET and MRS, we evaluated whether the combination of these techniques could overcome their individual deficiencies and lead to higher diagnostic accuracy for non-enhancing supratentorial glioma. In our study, the sensitivity differences between the combined approach and MRS or \textsuperscript{11}C-MET PET alone were significant. Compared with MRS, \textsuperscript{11}C-MET PET had enhanced sensitivity and equal specificity, which suggested its superiority to MRS. However, \textsuperscript{11}C-MET PET is radioactive, expensive, and poses practical difficulties. Thus, because MRS is more convenient, inexpensive, and non-radioactive, it may be an ideal first choice when non-enhancing glioma is highly suspected. If the CNI\textsubscript{max} is < 2.0 on MRS, then \textsuperscript{11}C-MET PET is highly recommended because it greatly reduces the rate of missed diagnoses. As a result, a combination of MRS and \textsuperscript{11}C-MET PET can substantially increase radiological diagnostic sensitivity for non-enhancing supratentorial gliomas without greatly reducing specificity.

However, the combination of MRS and \textsuperscript{11}C-MET PET may increase the number of false positives. An increased CNI\textsubscript{max} has been observed in other intracranial tumors, such as lymphoma (24), and some non-tumor lesions caused by encephalitis, demyelination, or vasculitis (25, 26). Demyelination, cerebral infarction, hematomas, or acute or subacute cerebral ischemia elevate \textsuperscript{11}C-MET uptake (8, 11). In our study, the false positives associated with the combination of MRS and \textsuperscript{11}C-MET PET included gliosis, focal cortical dysplasia granuloma, inflammation, granuloma, and demyelination. However, there was no significant difference in the number of false positives between the combined and individual approaches.

The combination of MRS and \textsuperscript{11}C-MET PET led clinicians to seek further histological or clinical diagnosis rather than resort to the wait-and-watch strategy. Although the wait-and-watch strategy has led to better quality of life scores in patients with suspected LGG (27), early surgical

---

**Fig. 3. Representative case of astrocytoma in 33-year-old woman.**

A. T1-weighted MRI showing low-intensity lesion in right frontal lobe. B. T2-weighted MRI showing hyperintense lesion in right frontal lobe. C. FLAIR MRI outlining margin of lesion. D. Non-enhanced lesion on post-contrast T1-weighted MRI acquired after Gd-DTPA injection. E. MRS result indicating glioma (CNI\textsubscript{max}, 3.04). F. \textsuperscript{11}C-MET PET showing no visible accumulation in lesion (SUV\textsubscript{max} 2.1; T/N ratio, 0.9). Surgery was performed based on combined MRS and \textsuperscript{11}C-MET PET findings, and diagnosis of astrocytoma was confirmed (WHO II). White square (□) shows ROI for CNI\textsubscript{max}, and white circle (○) shows ROI for calculating T/N ratio.
intervention has been associated with a longer overall survival time compared with this strategy (28). Afra et al. (29) found that the overall survival of patients with LGG was adversely impacted by seizure history duration prior to surgery and, therefore, recommended surgical intervention in patients with seizures and imaging results indicative of LGG. Several studies have reported that asymptomatic LGGs were safer to resect than symptomatic LGGs. Moreover, asymptomatic LGGs were associated with better overall survival. These findings suggest the potential benefits of performing surgery before lesions become symptomatic (30, 31). The early interventions described were based on sensitive auxiliary imaging methods used to avoid misdiagnosis, which supports the combination of MRS and 11C-MET PET as a more practical approach in clinical contexts.

Our study has some limitations. First, there is currently no consensus in the literature concerning the pathological CNImax and 11C-MET PET cut-off values. The use of different cut-off values may lead to divergent results. Therefore, a reliable cut-off value is needed. Moreover, our study was retrospective and based on a relatively small patient sample. Therefore, to validate our findings, a prospective study with greater patient recruitment and a longer follow-up period is needed.

In conclusion, the combination of MRS and 11C-MET PET can considerably improve accurate diagnostic sensitivity for non-enhancing supratentorial gliomas without significantly lowering specificity. This finding suggests that this combined approach should be highly reliable for clinical applications.

Conflicts of Interest
The authors have no potential conflicts of interest to disclose.

ORCID iDs
Dongxiao Zhuang https://orcid.org/0000-0002-4964-6529
Nijjati Kudulaiti https://orcid.org/0000-0002-8771-0288

REFERENCES

1. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 2014;16 Suppl 4:iv1-63

2. Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg 1993;79:533-536

3. Fouke SJ, Benzinger T, Gibson D, Ryken TC, Kalkanis SN, Olson JJ. The role of imaging in the management of adults with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2015;125:457-479

4. Wang W, Hu Y, Lu P, Li Y, Chen Y, Tian M, et al. Evaluation of the diagnostic performance of magnetic resonance spectroscopy in brain tumors: a systematic review and meta-analysis. PloS One 2014;9:e112577

5. Martinez-Bisbal MC, Celda B. Proton magnetic resonance spectroscopy imaging in the study of human brain cancer. Q J Nucl Med Mol Imaging 2009;53:618-630

6. Ha DH, Choi S, Oh JY, Yoon SK, Kang MJ, Kim KU. Application of 31P MR spectroscopy to the brain tumors. Korean J Radiol 2013;14:477-486

7. Guo J, Yao C, Chen H, Zhuang D, Tang W, Ren G, et al. The relationship between Cho/NAA and glioma metabolism: implementation for margin delineation of cerebral gliomas. Acta Neurochir (Wien) 2012;154:1361-1370; discussion 1370

8. Herholz K, Hölscher H, Bauer B, Schröder R, Voges J, Ernestus RI, et al. 11C-methionine pet for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316-1322

9. Demetriades AK, Almeida AC, Bangoo RS, Barrington SF. Applications of positron emission tomography in neuro- oncology: a clinical approach. Surgeon 2014;12:148-157

10. Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging 2013;40:615-635

11. Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004;10:7163-7170

12. Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H, et al. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 2008;29:1176-1182

13. Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Långström B, et al. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer 2001;92:1541-1549

14. Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T, et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 2003;98:1056-1064

15. Shishido H, Kawai N, Miyake K, Yamamoto Y, Nishiyama Y, Tamiya T. Diagnostic value of 11C-methionine (MET) and 18F-fluorothymidine (FLT) positron emission tomography in
Recurrence is a critical concern for high-grade gliomas; differentiation from treatment-induced tissue necrosis. *Cancers* (Basel) 2012;4:244-256

16. Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. *J Neurosurg* 2006;104:238-253

17. Matsuo M, Miwa K, Tanaka O, Shinoda J, Nishibori H, Tsuge Y, et al. Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning. *Int J Radiat Oncol Biol Phys* 2012;82:83-89

18. Grosu AL, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M, et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. *Int J Radiat Oncol Biol Phys* 2005;63:64-74

19. Mosskin M, Bergström M, Collins VP, Ehrin E, Eriksson L, von Holst H, et al. Positron emission tomography with 11C-methionine of intracranial tumors compared with histology of multiple biopsies. *Acta Radiol Suppl* 1986;369:157-160

20. Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. *J Nucl Med* 1998;39:778-785

21. Bulik M, Jancašek R, Vanicek J, Skoch A, Mechl M. Potential of MR spectroscopy for assessment of glioma grading. *Clin Neuroradiol Neurosurg* 2013;115:146-153

22. Narayana A, Chang J, Thakur S, Huang W, Karimi S, Hou B, et al. Use of MR spectroscopy and functional imaging in the treatment planning of gliomas. *Br J Radiol* 2007;80:347-354

23. Law M, Yang S, Wang H, Babbs JS, Johnson G, Cha S, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. *AJNR Am J Neuroradiol* 2003;24:1989-1998

24. Yamasaki F, Takayasu T, Nosaka R, Amatya VJ, Doskaliyev A, Akiyama Y, et al. Magnetic resonance spectroscopy detection of high lipid levels in intraxial tumors without central necrosis: a characteristic of malignant lymphoma. *J Neurosurg* 2015;122:1370-1379

25. Oz G, Alger JR, Barker PB, Bartha R, Bizzi A, Boesch C, et al. Clinical proton MR spectroscopy in central nervous system disorders. *Radiology* 2014;270:658-679

26. Baysal T, Ozisik HI, Karlidag R, Sarac K, Baysal O, Dusak A, et al. Proton MRS in Behcet's disease with and without neurological findings. *Neuroradiology* 2003;45:860-864

27. Reijneveld JC, Sitskoorn MM, Klein M, Nuyen J, Taphoorn MJ. Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas. *Neurology* 2001;56:618-623

28. Jakola AS, Myrnel KS, Kloster R, Torp SH, Lindal S, Uusgård G, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. *JAMA* 2012;308:1881-1888

29. Afra D, Osztie E, Sipos L, Vitanovics D. Preoperative history and postoperative survival of supratentorial low-grade astrocytomas. *Br J Neurosurg* 1999;13:299-305

30. Potts MB, Smith JS, Molinaro AM, Berger MS. Natural history and surgical management of incidentally discovered low-grade gliomas. *J Neurosurg* 2012;116:365-372

31. Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ. The role of surgery in the management of patients with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. *J Neurooncol* 2015;125:503-530